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Background: The Ovarian Protection Trial In Premenopausal Breast Cancer Patients “OPTION” trial
(NCT00427245) was a prospective, multicenter, randomised, open label study evaluating the frequency of
primary ovarian insufﬁciency (POI) at 12 months in women randomised to 6–8 cycles of (neo)adjuvant
chemotherapy (CT) þ/ goserelin (G). Here we report the results of a secondary endpoint analysis of the
effects of CTþ/-G on markers of bone turnover.
Methods: Serum for bone alkaline phosphatase (BALP) and urine for N-terminal telopeptide (NTX) were
collected at baseline, 6, 12, 18, 24 and 36 months. Changes in median levels of bone turnover markers
were evaluated for the overall population, according to age stratiﬁcation at randomisation (r40 vs 440
years) and with exploratory analysis according to POI rates at 12 months.
Results: In the overall population, there was a signiﬁcant increase in NTX at 6 months compared to
baseline in patients treated with CTþG (40.81 vs 57.82 p¼0.0074) with normalisation of levels thereafter.
BALP was signiﬁcantly increased compared to baseline at 6 months and 12 months in those receiving
CTþG, but normalised thereafter. BALP remained signiﬁcantly higher compared to baseline at 12, 24 and
36 months in patients receiving CT, resulting in a signiﬁcant difference between treatment groups at 36
months (CTþG 5.845 vs CT 8.5 p¼0.0006). These changes were predominantly seen in women 440
years. Women with POI at 12 months showed altered bone formation compared to baseline levels for a
longer duration than women who maintained menses.
Conclusion: Addition of G to CT increases bone turnover during treatment with normalisation after
cessation of treatment suggesting G may offer sufﬁcient ovarian protection against CT induced POI to
negate longstanding altered bone turnover associated with POI.
& 2016 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Maintenance of bone health relies on a balance between bone
formation by osteoblasts and bone resorption by osteoclasts. Un-
der normal physiological circumstances, these two processes areis an open access article under the
son),
ial.ac.uk (R. Leonard),
@nhs.net (D.J. Adamson),tightly regulated to ensure preservation of the structural integrity
of bone. However, cancer therapies can disrupt this delicate bal-
ance, leading to bone loss and subsequent increased fracture risk
[1]. The pathophysiology of cancer treatment induced bone loss
(CTIBL) is ascribed to either the direct effects of adjuvant treat-
ments on bone turnover i.e. chemotherapy and endocrine therapy,
or indirect effects via suppression of ovarian function with the
subsequent low oestrogen environment causing clinically relevant
bone loss [2].
Suppression of ovarian function in premenopausal women can
be temporary or permanent dependent on the type of cancer
treatment. The risk of POI is higher in women 440 yearsCC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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from direct chemotherapy toxicity depletes an already lowered
ovarian reserve secondary to age [4]. Chemotherapy induces per-
manent primary ovarian insufﬁciency (POI) in 63–85% of patients
receiving cyclophosphamide, methotrexate and ﬂuorouracil (CMF)
regimens and up to 50% with use of anthracycline containing re-
gimens [5,6] with effects on bone metabolism and bone mineral
density (BMD) as a consequence. For example, following induction
of permanent ovarian suppression by six cycles of doxorubicin and
cyclophosphamide chemotherapy, BMD fell at 6 months by 5.2% at
the lumbar spine and by 2.8% at the femoral neck compared to
baseline [7]. Bone loss associated with treatment induced ovarian
failure appears to be more rapid and severe than the bone loss that
occurs during a natural menopause, and therefore carries an in-
creased risk of skeletal morbidity in long term survivors of pre-
menopausal breast cancer [8]
Gonadotrophin-releasing hormone (GnRH) analogues, such as
goserelin, induce a rapid but reversible suppression of ovarian
function with serum levels of oestradiol and follicle stimulating
hormone (FSH) reaching postmenopausal levels within 2 weeks of
administration [9,10]. In addition to the adjuvant use of goserelin
in endocrine sensitive breast cancer, GnRH analogues have been
evaluated in prospective randomized trials as a possible protection
against chemotherapy induced POI in premenopausal women re-
ceiving adjuvant chemotherapy. Conﬂicting results have been re-
ported with some studies demonstrating a reduction in che-
motherapy induced early menopause of between 17% and 56%
with addition of goserelin [11,12], while others showed no sta-
tistical difference in resumption of menses post chemotherapy
between those treated with or without goserelin [13,14]. The im-
pact of combined GnRH and chemotherapy on acute bone loss
during therapy, and the delayed effects on bone post treatment
have not been reported to date. Herein we present the secondary
endpoint of bone turnover marker changes (serum bone alkaline
phosphatase [BALP] and urine N-terminal telopeptide [NTX]) in
the OPTION trial. The preliminary primary endpoint data of ame-
norrhoea rates at 12 months post chemotherapy were not statis-
tically different between those treated with or without goserelin
[14], although ﬁnal data have not been reported yet.2. Patients and methods
2.1. Study population
The OPTION trial was an open, randomised multicenter study
registered on the ClinialTrials.gov website, number NCT00427245.
The trial was approved by South West Research Ethics Committee
and performed in accordance with ICH GCP and the EU Directive.
The primary objective was to evaluate the effect of goserelin on
the incidence of POI at 12 months following chemotherapy in early
breast cancer. All premenopausal ER negative women (or ER po-
sitive women for whom ovarian suppression was not considered
necessary as part of the adjuvant therapy programme) re-
commended to receive (neo)adjuvant chemotherapy were eligible
for inclusion. The average age of patients was 40. Women were
stratiﬁed by age at randomisation (r40 or 440 years) and by
centre. Chemotherapy (CT) regimens comprised 6–8 cycles of cy-
clophosphamide and/or anthracycline and/or taxane. Goserelin
(G) 3.6 mg by depot subcutaneous injection was randomly allo-
cated to start before or at ﬁrst chemotherapy cycle and continued
3–4 weekly until the ﬁnal cycle of chemotherapy. At trial closure
227 patients had been randomised and all had given written in-
formed consent for serum and urine analysis.2.2. Patient evaluation
Secondary objectives of the OPTION trial included measure-
ment of changes in bone turnover markers. Baseline serum and
urine samples were available from 89 and 94 patients respectively.
The serum and urine was stored at 80 °C pending batch analysis
at Shefﬁeld University’s Academic Unit of Bone Metabolism. Pa-
tients were excluded from this analysis if they did not have a
follow up time point sample. Follow up time points were 6, 12, 18,
24 and 36 months post baseline. BALP was measured using the
AcessÒ automated immunoassay, Beckman Coulter Inc (High
Wycombe, United Kingdom). The inter assay coefﬁcient of varia-
tion (CV)¼5.2%. NTX and creatinine were measured using the
Ortho Clinical Diagnostics automated immunoassay (High Wy-
combe, United Kingdom). The inter assay CV¼4.4%. NTX was ex-
pressed as a ratio to creatinine and the inter assay CV for
creatinine¼1.8%.
2.3. Statistical analysis
Changes in median levels of bone turnover markers from
baseline and between treatment groups were evaluated using the
Mann Whitney u test. All analyses were performed using Graph-
Pad PRISM v 6.0d. Signiﬁcance was assigned at pr0.05.3. Results
Of the 89 and 94 patients who provided serum and urine, 58
(serum) and 65 (urine) patients had at least one follow up sample
and were included in the analyses (Fig. 1). The bone marker po-
pulation had an average age of 38 years and predominantly ER
positive tumours. The percentage of patients receiving anthracy-
cline only (23%), anthracyclineþcyclophosphamide (72%) or tax-
ane (4%) chemotherapy was identical to the overall study popu-
lation. Within this sub group treatment groups were well matched
for age with a median (range) age of 41.5 years (30–51) in the CT
alone group (n¼54) and 41.0 years (26–49) in the CTþG group
(n¼54). Baseline BALP and NTX were similar between CT and
CTþG groups with a median [IQR] BALP (μg/l) of 6.1 [4.9–7.9] and
6.3 [4.7–7.5] respectively and a median [IQR] NTX (nmol/mmol
creatinine) of 33.9 [23.3–43.2] and 34.9 [28.8–47.2] respectively.
Adjuvant tamoxifen use was similar between both groups (CT
n¼20, CTþG n¼22).
3.1. Bone resorption
Acute/on treatment median [IQR] NTX was signiﬁcantly in-
creased at 6 months (6/12) in patients treated with CTþG (6/
12¼57.8 [39.4–72.9] p¼0.0030). This acute effect on bone re-
sorption was not seen in patients treated with CT (37.07 [27.5–
59.1]), resulting in a signiﬁcantly higher NTX level at 6 months in
the CTþG group compared with the CT group (p¼0.0032)
(Fig. 2a).
Subsequently, following completion of G treatment at around
12–18 months, NTX returned to near baseline levels in the CTþG
group with no signiﬁcant differences from baseline at any further
time point, indicating the acute G-induced increase in bone re-
sorption resolved upon cessation of the drug. CT did not sig-
niﬁcantly change bone resorption compared to baseline at any
time points.
3.2. Bone formation
Acute/on treatment median [IQR] BALP was signiﬁcantly in-
creased at 6/12 compared to baseline in patients treated with
Fig. 1. Summary of patients included in the bone marker analysis.
Fig. 2. Changes in bone resorption and bone formation markers in the overall study population.
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This acute effect on bone formation was not seen in patients
treated with CT (Fig. 2b).
Following completion of goserelin treatment, median [IQR]
BALP remained signiﬁcantly elevated compared to baseline at 12/
12 in patients treated with CTþG (12/12¼ 9.2 [6.5–11.1]
p¼0.0043), and is likely to reﬂect a delayed coupling of bone
formation to resorption following the increase in bone resorption
induced by goserelin. BALP returned to baseline levels in patients
treated with CTþG at all further time points with no signiﬁcant
difference compared to baseline. In patients treated with CT alone,
BALP was signiﬁcantly increased compared to baseline at 12/12(8.1 [7.6–9.9] p¼0.001), 24/12 (8.0 [6.8–9.6] p¼0.0145) and 36/12
(8.2 [7.2–11.1] p¼0.012) suggesting a delayed and lasting ab-
normality of bone turnover in this group.
3.3. Changes in bone turnover according to age stratiﬁcation
In the main trial, patients were stratiﬁed according to age
(r40 or 440 years). We evaluated if age inﬂuenced the effects of
treatment on bone turnover. In patients r40 years neither BALP
or NTX changed signiﬁcantly compared to baseline in either
treatment group with the exception of NTX at a single time point
(24/12) in the CT alone group; however, this is likely to be a chance
Fig. 3. Changes in bone turnover markers according to age.
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440 the results mirrored the main bone marker analysis, with a
signiﬁcant increase in median [IQR] NTX in the CTþG group at 6/
12 compared to baseline (baseline: 37.6 [30.4–50.7], 6/12: 59.1
[41.0–81.9], p¼ 0.0128). As in the main analysis, no change in NTX
was seen in the CT group at 6/12 which resulted in a signiﬁcant
difference in NTX between treatment groups at this time point
(CTþG; 59.1 [41.0–81.9], CT;37.7 [28.0–61.6] (p¼0.0451)). The
signiﬁcant increase in median [IQR] BALP at 12/12 in CTþG pa-
tients was also seen (baseline 5.7 [4.6–7.5], 12/12 7.7 [6.3–10.5]
p¼0.0472) with a return to baseline levels at all further time
points. The CT group again showed persistently signiﬁcantly ele-
vated BALP compared to baseline at 12/12 (p¼0.0039) and 36/12
(p¼0.013) resulting in a signiﬁcantly higher BALP at 36/12 in the
CT group compared to CTþG (p¼0.017). These data suggest that
the persistent alteration in bone turnover several years post
completion of chemotherapy alone was largely restricted to thoseaged 440. This effect is not seen in women aged r40 treated
with CTþG, who show early normalisation of bone turnover
markers after completion of treatment by 12/12 (Fig. 3C and D).
3.4. Exploratory analysis of changes in bone turnover according to
POI at 12 months
Changes in bone markers over time were analysed in those
patients for whom the primary endpoint data of POI at 12 months
was known. Although median BALP levels were higher in ame-
norrhoeic women compared to menstruating women at 6/12 and
12/12, and median NTX was higher at 12/12 and 18/12 in ame-
norrheic women, the changes were not statistically signiﬁcant
between menstrual groups (Fig. 4A and B). However, in women
who were amenorrheic median [IQR] BALP was signiﬁcantly
higher than baseline at 6/12 (baseline 5.6 [4.7–7.6], 6/12 7.8 [6.0–
9.4] p¼0.0063), 12 months (9.4 [7.6–11.5] p¼o0.0001) and 18
Fig. 4. Changes in bone turnover markers according to menstrual status at 12 months.
Fig. 5. Treatment related changes in BALP according to menstrual status at 12 months.
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menstruation did not demonstrate a signiﬁcant alteration in BALP
during follow up (apart from a single time point (12/12) at which
BALP was raised compared to baseline, although this may be a
change ﬁnding as no other time points were signiﬁcantly different
to baseline). NTX was signiﬁcantly raised compared to baseline in
both menstruating (p¼0.016) and amenorrhoeic (p¼0.035) wo-
men at 6/12. These data suggest that women who experience POI
at 12 months have altered bone formation that persists for at least
12 months post completion of adjuvant therapy. In addition, in
womenwho developed POI at 12 months, the addition of goserelin
to chemotherapy prevented long term alterations in BALP com-
pared to chemotherapy alone after completion of adjuvant therapy
(Fig. 5B), suggesting that sufﬁcient ovarian function may be pre-
served to maintain normal bone turnover. However, the numbers
of patients are small and the data should be considered
exploratory.4. Discussion
In this secondary endpoint analysis of the OPTION trial, we have
shown that the addition of goserelin to neo(adjuvant) che-
motherapy temporarily increased bone turnover during treatment
and that this reverses over the next 6–12 months after completion
of treatment. This is probably mediated by the effects on ovarian
function, with a rapid and profound fall in oestradiol levels but,
once the drug is stopped, ovarian function resumes to a level that
is sufﬁcient to maintain normal bone turnover, even if this is not
manifested by a demonstrable difference in the frequency of
chemotherapy induced amenorrhoea. We found no acute direct
effect of chemotherapy on bone turnover markers, but there was a
delayed effect on bone with increased bone turnover starting at
6 months after completion of chemotherapy and continuing
throughout the 36 months of observation. This was predominantly
in women aged 440 years and in those women who developed
chemotherapy induced amenorrhoea, suggesting there may not be
a direct toxic effect of chemotherapy on bone but that the BMD
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itations that include a lack of ovarian function information beyond
12 months, which limits the interpretation of the association be-
tween bone markers and POI after this time point. In addition the
number of serum/urine samples available for the bone marker
analysis decreased during follow up thus limiting the interpreta-
tion of data at later time points.
We found that BALP remained persistently raised following
completion of adjuvant therapy in women who experienced POI at
12 months, an effect not seen in menstruating women. Cameron
et al. showed that BALP and serum CTX increased during che-
motherapy in women who continue to menstruate (n¼16) but
normalised after cessation of treatment, whereas women who are
amenorrheic (n¼25) at the end of chemotherapy show a con-
tinuing rise in BALP [15], an observation that supports our ﬁnd-
ings. This altered bone turnover appears to persist and leads to
evidence of bone loss at 5 years post chemotherapy that is more
marked in women who develop amenorrhoea (lumbar spine BMD;
11.3%70.9%) than those who maintain menses (lumbar spine
BMD; 6.4%71.2% respectively) [16].
In support of this, BMD loss following 6 months of CMF che-
motherapy treatment in premenopausal breast cancer patients has
been demonstrated at both the lumbar spine (5.9%) and the
femoral neck (2%) at 2 years, with the largest changes in those
patients who developed POI. [17]. Similarly, osteoporosis-free
survival at 10 years following CMF chemotherapy is higher in
menstruating women (100%) than those with irregular menses
(69%) or amenorrhoea (67%) [18]. Therefore, patients with POI are
at long term risk of bone loss.
This study has focused on the bone turnover markers NTX and
BALP. In previous studies elevated NTX and BALP have been shown
to correlate with risk of skeletal complications in patients with
bone metastases from solid tumours and myeloma [19]. Moreover,
clinical trials of anti-bone resorptive therapies i.e. bispho-
sphonates have demonstrated that lowering of bone turnover
marker values to premenopausal levels reduces fracture risk [20–
22]. Thus the persistent changes in bone turnover markers seen in
our study have potential implications for subsequent fracture risk.
The effects of permanent and temporary ovarian suppression
on bone have been evaluated in prospective breast cancer trials
comparing chemotherapy to GnRH analogues in premenopausal
women. Evaluation of BMD was undertaken in the bone sub-study
of the ZEBRA trial (Zoladex in Early Breast Cancer Research Asso-
ciation) which compared 6x CMF with 2 years of goserelin; at
2 years BMD losses at lumbar spine and femoral neck compared to
baseline were 10.5% and 6.4% with goserelin, and 6.5% and
4.5% with CMF [23]. However at 3 years (12 months after com-
pletion of goserelin) BMD at both anatomical sites partially re-
covered in the goserelin cohort compared to persistent loss in the
CMF cohort. Amenorrhoea was observed in 100% of patients
treated with goserelin and 64% treated with CMF at 2 years,
however, there was resumption of menses in 73% of the goserelin
group at 3 years but continued amenorrhoea in 76.5% CMF
patients.
The acute effects of goserelin on bone have also been evaluated
by prospective trials of goserelinþ/ adjuvant tamoxifen. The
Zoladex in Premenopausal Patients trial randomized 89 women
with early breast cancer to goserelinþ/ tamoxifen, tamoxifen
alone and no endocrine therapy. After 2 years of treatment there
was a signiﬁcant reduction in BMD of 5% in patients receiving
goserelin alone with partial recovery in BMD of 1.5% at 12 months
post cessation of treatment [24].
The role of goserelin to protect against chemotherapy induced
POI is controversial. However, the POEMS study recently reported
preliminary results that are likely to increase the use of this
therapeutic strategy [25]. POEMS randomised 257 premenopausalpatients with ER-ve breast cancer to standard cyclophosphamide
containing chemotherapy alone or with monthly goserelin 3.6 mg.
The primary endpoint was 2 year POI with secondary endpoints
that included survival and pregnancies. POI rates were 22% in
standard arm and 8% in the goserelin arm (p¼0.03). There were
more pregnancies in the goserelin arm (22 vs 13 p¼0.05). Re-
markably in this ER-ve population, disease free and overall survi-
val were also improved in the goserelin arm.
In conclusion, our data are the ﬁrst to show that concomitant
use of chemotherapy and goserelin may protect ovarian function
sufﬁciently to prevent long term deleterious effects on bone
turnover. In young women who experience POI as a result of
chemotherapy it will be important that bone health assessment is
carried out as part of their longer term follow up [26, 27].Role of funding Source
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